[Variables of arrhythmia risk in relation to pacemaker and implantable defibrillator].
Patients suffering from heart failure are at high risk of arrhythmic death. Conventional pacemakers have not shown to affect mortality in patients with chronic heart failure and sick sinus syndrome, while this issue is established in patients with III degree or advanced atrioventricular block. Biventricular pacing has recently been introduced in clinical practice and the experience is limited; to date, only an improvement in symptoms and quality of life has been shown. Biventricular pacing with implantable cardioverter-defibrillator back-up is promising. The implantable cardioverter-defibrillator is able to reduce total and sudden mortality in high risk patients, as clearly demonstrated by several randomized clinical trials.
Solano
A
A
Centro Aritmologico, Ospedali Riuniti, Via Don Bobbio 16033 Lavagna, GE.
Oddone
D
D
Croci
F
F
Donateo
P
P
Puggioni
E
E
Brignole
M
M
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D017147:Defibrillators, Implantable; D006323:Heart Arrest / Q000517:prevention & control; D006327:Heart Block / Q000628:therapy; D006333:Heart Failure / Q000150:complications* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D010138:Pacemaker, Artificial; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012804:Sick Sinus Syndrome / Q000628:therapy; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000503:physiopathology; D014693:Ventricular Fibrillation / Q000628:therapy
D000889:Anti-Arrhythmia Agents